ArticleInternational journal of women's health2025
Temporal Trends of Polycystic Ovary Syndrome Burden in the East and Southeast Asia from 1990 to 2021: An Analysis from the Global Burden of Disease Study 2021.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Burden of polycystic ovary syndrome in low-and middle-income countries, 1990-2023: results from the global burden of disease study 2023.Tropical medicine and health · 2026Article
- Burden and Risk Factor Patterns of Reproductive System Tumors and Non-Tumor Diseases Among Asian Women, 1990-2021: Evidence from the GBD Study.International journal of women's health · 2026Article
- Global Burden and Future Trends of Polycystic Ovary Syndrome: Insights from the GBD 2021 Study.International journal of women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine disorders among women of reproductive age. This study aims to assess the current burden of PCOS in East and Southeast Asia and analyze its spatiotemporal trends over the past three decades. Patients and Methods: Data on the prevalence, incidence, and years lived with disability (YLDs) due to PCOS from 1990 to 2021 were extracted from the GBD 2021. The spatiotemporal trends of PCOS were comprehensively analyzed across multiple levels. Age-Period-Cohort (APC) models were utilized to assess the influence of age, period, and birth cohort on the burden of PCOS, and the future burden of PCOS in the next 10 years was predicted using the autoregressive integrated moving average (ARIMA) model. Results: In 2021, the estimated number of prevalent cases of PCOS was approximately 10,490,358.5 (95% UI: 7,423,407.5-14,808,757.1) in East Asia and 10,520,027.7 (95% UI: 7,378,813.9-14,809,823.5) in Southeast Asia. The age-standardized prevalence rates (ASPR) of PCOS in East and Southeast Asia were 1548.4 per 100,000 women (95% UI: 1085.5-2170.7) and 2842.7 per 100,000 women (95% UI, 1993.2-3997.5), respectively. Moreover, the ASPR of PCOS exhibited an upward trend from 1990 to 2021. The burden of PCOS varied substantially between countries and age groups, and was positively correlated with SDI levels. PCOS burden showed an increased trend with age, and the period and cohort risk also showed a significant upward trend when compared to the reference groups. Additionally, the burden of PCOS is expected to continue to increase in East Asia by 2031, while it remains stable in Southeast Asia. Conclusion: The increasing burden of PCOS has become a public health problem in the East and Southeast Asia region. The development of appropriate health measures and strategies to prevent and manage PCOS has become extremely urgent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.